Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 37/75 ]
NASDAQ | Common Stock
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin.
It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions.
In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers.
Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 26 | 1.31 Decreased by -27.17% | 1.47 Decreased by -10.82% |
| Nov 4, 25 | 1.32 Increased by +53.49% | 1.20 Increased by +10.00% |
| Aug 5, 25 | 1.33 Increased by +54.65% | 1.22 Increased by +9.02% |
| May 6, 25 | 1.36 Increased by +106.06% | 1.21 Increased by +12.40% |
| Feb 25, 25 | 1.80 Increased by +69.81% | 1.42 Increased by +26.76% |
| Nov 5, 24 | 0.86 Increased by +36.51% | 0.84 Increased by +2.38% |
| Aug 6, 24 | 0.86 Increased by +38.71% | 0.76 Increased by +13.16% |
| May 7, 24 | 0.66 Decreased by -24.14% | 0.69 Decreased by -4.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 412.50 M Decreased by -31.33% | 68.30 M Increased by +119.54% | Increased by +16.56% Increased by +128.45% |
| Sep 30, 25 | 371.50 M Decreased by -26.38% | -100.40 M Decreased by -1.12 K% | Decreased by -27.03% Decreased by -1.49 K% |
| Jun 30, 25 | 370.90 M Increased by +7.85% | 51.30 M Increased by +220.62% | Increased by +13.83% Increased by +197.28% |
| Mar 31, 25 | 372.00 M Increased by +9.54% | -170.70 M Decreased by -1.00 K% | Decreased by -45.89% Decreased by -924.51% |
| Dec 31, 24 | 600.70 M Increased by +9.44% | -349.60 M Decreased by -1.13 K% | Decreased by -58.20% Decreased by -1.04 K% |
| Sep 30, 24 | 504.60 M Increased by +5.37% | 9.80 M Decreased by -7.55% | Increased by +1.94% Decreased by -12.26% |
| Jun 30, 24 | 343.90 M Decreased by -24.47% | 16.00 M Increased by +1.91% | Increased by +4.65% Increased by +34.92% |
| Mar 31, 24 | 339.60 M Decreased by -39.89% | 18.90 M Decreased by -11.27% | Increased by +5.57% Increased by +47.63% |